Combining Losoxantrone and Cyclophosphamide for Solid Tumors
Author Information
Author(s): Goh B C, Vokes E E, Joshi A, Ratain M J
Primary Institution: University of Chicago
Hypothesis
Can losoxantrone combined with cyclophosphamide be safely administered to patients with refractory solid tumors?
Conclusion
The study found that neutropenia was the main dose-limiting toxicity, and the maximum tolerated dose of losoxantrone was determined to be 125 mg/m² when combined with cyclophosphamide.
Supporting Evidence
- Neutropenia was the main dose-limiting toxicity observed in the study.
- The maximum tolerated dose of losoxantrone was determined to be 125 mg/m².
- Cardiotoxicity was noted with cumulative dosing of losoxantrone.
- No objective responses were observed in the study.
Takeaway
Doctors tested a new drug combination to help patients with tough-to-treat cancers, but they found that one of the drugs caused a lot of side effects.
Methodology
Patients received a fixed dose of cyclophosphamide and escalating doses of losoxantrone every three weeks, with evaluations for toxicity and pharmacokinetics.
Potential Biases
The study's findings may be influenced by the small sample size and the early termination.
Limitations
The study was terminated early due to sponsor decision, limiting the opportunity to gather more data on higher doses.
Participant Demographics
Patients were 18 years or older with solid malignancies refractory to standard chemotherapy.
Statistical Information
P-Value
0.002
Statistical Significance
p=0.002
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website